Didactic Series. Latent TB Infection in HIV Infection

Similar documents
Didactic Series. Latent TB Infection in HIV Infection

TB Intensive Tyler, Texas December 2-4, 2008

TB Nurse Case Management San Antonio, Texas July 18 20, 2012

TB Intensive San Antonio, Texas November 11 14, 2014

Latent TB Infection (LTBI)

TB Intensive Houston, Texas October 15-17, 2013

Evaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014

Using Interferon Gamma Release Assays for Diagnosis of TB Infection

2016 OPAM Mid-Year Educational Conference, Sponsored by AOCOPM Sunday, March 13, 2016

Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis

10/3/2017. Updates in Tuberculosis. Global Tuberculosis, WHO 2015 report. Objectives. Disclosures. I have nothing to disclose

Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University

Peggy Leslie-Smith, RN

Evaluation and Management of the Patient with Latent Tuberculosis Infection (LTBI)

Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016

Diagnosis Latent Tuberculosis. Disclosures. Case

Screening of HIV-Infected Patients with IGRAs for LTBI. Background. Tuberculosis is the most prevalent in the world.

TB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012

TB in Corrections Phoenix, Arizona

Latent TB Infection (LTBI) Strategies for Detection and Management

Approaches to LTBI Diagnosis

TB Update: March 2012

Diagnosis and Medical Case Management of Latent TB. Bryan Rock, MD April 27, 2010

Barbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and Infectious Disease UT Health Northeast

Tuberculosis Update. Topics to be Addressed

Diagnosis and Medical Management of TB Infection Lisa Y. Armitige, MD, PhD September 12, TB Nurse Case Management September 12 14, 2017

CHILDHOOD TUBERCULOSIS: NEW WRINKLES IN AN OLD DISEASE [FOR THE NON-TB EXPERT]

Case Management of the TB/HIV Infected Patient

Screening for Tuberculosis Infection. Harlingen, TX. Linda Dooley, MD has the following disclosures to make:

Diagnosis and Management of Latent TB Infection Douglas Hornick, MD September 27, 2011

Tuberculosis Tools: A Clinical Update

LATENT TUBERCULOSIS. Robert F. Tyree, MD

Disclosures. Updates in TB for the PCP: Opportunities for Prevention. Objectives PART 1: WHY TEST? 4/14/2016. None

ESCMID Online Lecture Library. by author

Making the Diagnosis of Tuberculosis

Latent TB Infection Treatment

Tuberculosis in Primary Care COC GTA Spring Symposium Dr Elizabeth Rea April 2013

Technical Bulletin No. 172

What the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Global Impact of TB

Understanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010

Latent TB, TB and the Role of the Health Department

Treatment of TB Infection Lisa Y. Armitige, MD, PhD April 7, 2015

QuantiFERON-TB Gold Plus

Latent Tuberculosis Best Practices

New Approaches to the Diagnosis and Management of Tuberculosis Infection in Children and Adolescents

Testing for TB. Bart Van Berckelaer Territory Manager Benelux. Subtitle

TB Prevention Who and How to Screen

Investigation of false-positive results by the QuantiFERON-TB Gold In-Tube assay

What the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Life Cycle of M. tuberculosis

New Standards for an Old Disease:

TB Screening and Diagnosis

ATTACHMENT 2. New Jersey Department of Health Tuberculosis Program FREQUENTLY ASKED QUESTIONS

Pre-Treatment Evaluation. Treatment of Latent TB Infection (LTBI) Initiating Treatment: Patient Education. Before initiating treatment for LTBI:

Conflict of Interest Disclosures:

Treatment of Latent TB Infection (LTBI)

Tuberculosis: Where Are We Now?

Interpretation of TST & IGRA results. Objectives

Michael J. Huey, MD. NYSCHA Annual Meeting WE-2, October 19, 2016

Tuberculosis. WRAIR- GEIS 'Operational Clinical Infectious Disease' Course UNCLASSIFIED

TUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of

11/1/2017. Disclosures. Update In Tuberculosis, Indiana Outline/Objectives. Pathogenesis of M.tb Global/U.S. TB Burden, 2016

Testing & Treatment for TB Infection: Blood Tests, Skin Tests, Who to Screen & Who to Treat?

Sharing the Care: Working Together on LTBI Treatment and Management Webinar. September 24, Curry International Tuberculosis Center

Management of Patients with TB Infection Catalina Navarro, RN, BSN April 7, 2015

Diagnosis and Medical Management of LTBI

Targeted Testing and the Diagnosis of. Latent Tuberculosis. Infection and Tuberculosis Disease

TB Classification (ATS/CDC)

TB PREVENTION: TREATMENT OF LATENT TB INFECTION AND BCG VACCINATION

5. HIV-positive individuals treated with INH should receive Pyridoxine (B6) 25 mg daily or 50 mg twice/thrice weekly on the same schedule as INH

Interferon Gamma Release Assay Testing for Latent Tuberculosis Infection: Physician Guidelines

Identifying TB co-infection : new approaches?

ATS/CDC Guidelines for Treating Latent TB Infection

Management of Pediatric Tuberculosis in New Jersey

Tuberculosis Intensive

Diagnosis and Medical Management of Latent TB Infection

Pediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017

TB Laboratory for Nurses

8/28/2017. Learning Objectives. After attending this presentation, learners will be able to:

Contracts Carla Chee, MHS May 8, 2012

Effect of prolonged incubation time on the results of the QuantiFERON TB Gold In-Tube assay for the diagnosis of latent tuberculosis infection

TUBERCULOSIS. Presented By: Public Health Madison & Dane County

Self-Study Modules on Tuberculosis

Tuberculosis (TB) Fundamentals for School Nurses

Tuberculin Skin Test (TST) and Interferon-gamma Release Assays (IGRA)

Tuberculosis and Diabetes Mellitus. Lana Kay Tyer, RN MSN WA State Department of Health TB Nurse Consultant

TUBERCULOSIS. Pathogenesis and Transmission

Detecting latent tuberculosis using interferon gamma release assays (IGRA)

Role of the Laboratory in TB Diagnosis and Management

Errors in Dx and Rx of TB

PREVENTION OF TUBERCULOSIS. Dr Amitesh Aggarwal

Latent Tuberculosis Infection Controversies in Diagnosis and Management of LTBI

How to interpret the new QuantiFERON- TB Gold Plus test (QFT-Plus)

TB Nurse Case Management San Antonio, Texas March 7 9, Clinical Diagnosis and

Advanced Concepts in Pediatric Tuberculosis

TB Epidemiology. Richard E. Chaisson, MD Johns Hopkins University Center for Tuberculosis Research

Tuberculosis Infection in the US Military

Contact Investigation and Prevention in the USA

Advanced Management of Patients with Tuberculosis Little Rock, Arkansas August 13 14, 2014

Transcription:

Didactic Series Latent TB Infection in HIV Infection Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director SF, North Coast and East Bay AETC January 8, 2015 ACCREDITATION STATEMENT: University of California, San Diego School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The University of California, San Diego School of Medicine designates this educational activity for a maximum of one credit per hour AMA PRA Category 1 Credits. Physicians should only claim credit commensurate with the extent of their participation in the activity. 1

Learning Objectives Identify principles of TB screening in HIV infected patients Discuss treatment and prevention recommendations Review cases of HIV and LTBI patients 2

A patient for TB screening AC is 52 yo Af-Am man 10 yr hx of HIV+ on ART. CD4 270, nadir 120, VL UD. Major co-morbidity is HAND, Hep C and crack cocaine dependence (daily user). New to you, 2006 QFT +, no hx of Rx for LTBI. No symptoms of TB. 1. What to do about his QFT+ hx? a) It was over 2 years ago, no eval needed b) No symptoms, so CXR only c) Place a TB Skin Test (TST) d) Other approach 3

US 2013 TB Cases MMWR Annual TB Report May 2014 Total cases of TB 9,588 CA, FL, NY, TX > 50% all cases Foreign-born 64.6% TB and HIV+ 6.8% 5

Why the HIV/TB Association? HIV induced immune defects => decreased TB control systems 5-8%/year activation instead of 10% over a lifetime Its all about the T-cells! Latent TB Infection (LTBI) in dormant phase Lower T-cells (particularly CD4), empower the Mycobacterium Lower CD4 cells also dis-empower TB screening 6

HIV-TB Screening Issues TST/IGRA/CXR/symptom review Repeating LTBI tests in HIV patients Screening prior positives LTBI management after contact to a case 7

A word about BCG Live vaccine Bacillus of Calmette and Guerin (BCG) Attenuated Mycobacterium Bovis -- Not ROUTINELY recommended for known HIV+ Evaluation of TST reactions in persons vaccinated with BCG should be interpreted using the same criteria for those not BCGvaccinated 8

Pearls about TB Skin Test (TST) Read at 48-72 hours, but positive can persist for days > 5mm of induration is positive FOR Recent contacts Immune compromised > 10mm if not high risk Don t repeat if positive 9

Blood Tests for TB Screening Interferon γ releasing assays (IGRAs) Whole blood (5cc) test Measures immune reactivity to M. tb QuantiFERON Gold-In Tube(QFT-GIT) and T- spot both FDA approved Does not tell LATENT from ACTIVE TB

How Quantiferon Is Performed Stage 1 Whole Blood Culture Nil Control Avian PPD Tb PPD Mitogen Control Heparinized whole blood Transfer undiluted whole blood into wells of a culture plate and add antigens Culture overnight at 37 o C TB infected individuals respond by secreting IFN-γ Stage 2 IFN-gamma ELISA Harvest plasma from above settled cells and incubate 60 min in Sandwich ELISA COLOR TMB Wash, add substrate, incubate 30 min then stop reaction IFN-γ IU/ml OD 450nm Standard Curve Measure OD, determine IFN-γ levels and interpret test

Interpreting QFT Gold IN-Tube Positive or Negative or Indeterminate Negative : M. TB infection NOT likely Nil = 0.18 TB Antigen-NIL = 0.05 Mitogen-Nil = 7.33 Positive would have TB Antigen-Nil >0.35 Indeterminate is uninterpretable

IGRAs in 2014 Can be used like TST for screening Distinguishes Mtb, Mkansasii, Mbovis Help in BCG vaccinated (Mbovis) persons Flip/Flop results may be due to waning More specific than sensitive (false negatives) Cost issues remain

Summary LTBI Testing 2014 Use screening test that is most available Positives = positive Indeterminate can t be interpreted If test is negative and it matters a lot Repeat screening with other type of test and Repeat TB screening when CD4 goes over 200 cells 14

Treatment for LTBI Traditional INH 5mg/kg (max 300mg) daily or 900mg 2 x a week Other options - Rifampin/rifabutin daily for 4 months 3 months (12 doses) by DOT in HIV* INH 15mg/kg (max 900mg) weekly AND Rifapentine wgt-based dose (max 900mg) weekly * Not for Pregnant or expect to get pregnant; children <2yrs 15

Screening TB that is HIV Specific Blood cultures for M. tb higher yield in HIV CD4 count <100, get single mycobacterial culture when febrile Extra-pulmonary TB common, 25-40% multi-site infection Get CXR and sputum AFB cultures even if extra-pulmonary site found 16

Ongoing Screening for LTBI in HIV HIV program protocols ---TB screening on entry Repeat based on risk of exposure Disease-based (HIV) screening -- Prior to starting ART Repeat if CD4 rises above 200 cells/ml 17

A patient for TB screening AC is 52 yo Af-Am man 10 yr hx of HIV+ on ART. CD4 270, nadir 120, VL UD. Major co-morbidity is HAND, Hep C and crack cocaine dependence (daily user). New to you, 2006 QFT +, no hx of Rx for LTBI. No symptoms of TB. 1. What to do about his QFT+ hx? If CXR normal, would offer treatment for LTBI. INH 900mg 2 x a week by DOT chosen. 18

When is Empiric Rx of LTBI Appropriate? Q. What is the Window Period for LTBI For contacts to a TB case - 3 months between initial LTBI negative and final screening Q. Why does it matter more in HIV+? Hyper rapid evolution to active TB after exposure Ex: AIDS residential program outbreak 37% exposed became active TB in 15 weeks 19

Summary LTBI Treatment R/O active TB then start INH or INH/Rifapentine in high risk pts HIV + or contacts to a case if HIV A reason to test is a reason to treat, so test thoughtfully INH in pregnancy, HIV+ or high risk pt Add B6 10-25mg daily for neuropathy Close monitoring of symptoms and signs hepatitis Lower risk pts, wait 2-3 months post partum 20

HIV TB/HIV Summary Makes it harder to screen for LTBI TB more likely to activate, higher TB mortality Rescreen after starting ART or CD4 >200 cells Screen all HIV patients for TB and all TB patients for HIV LTBI Rx: INH 9 months or Rif 4 months INH+Rifapentine 12 weekly doses by DOT 21

A patient for TB screening AC started INH 2 x a week DOT. At about week 10, he was complaining of numbness in his right fingers and toes on the tips. What is your approach? How to evaluate and what intervention?? At 4 months, his monthly ALT was 3 x normal. Asymptomatic, denies ETOH or higher dose acetaminophen. Now what? 22

Resources TB Warmline 877-390-6682 or (415) 502-4700 Mon-Fri leave message AETC National Resource Center http://www.aids-etc.org/ AIDSinfo: HIV/TB Treatment Guidelines http://aidsinfo.nih.gov/ HIV InSite http://hivinsite.ucsf.edu/insite TB Center http://www.currytbcenter.ucsf.edu 23